Purple Biotech

Tumor-immune Evasion and Drug Resistance Therapies

Active Public Startup Rehovot Founded 1968-08

Website ↗ LinkedIn

Purple Biotech is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company’s oncology pipeline includes NT219, CM24 and IM1240. *NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. In a Phase 1/2 study of NT219, the Company is currently…